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A B S T R A C T
Several studies have now confirmed that optimal targets of blood pressure (BP) could 
rarely be reached by monotherapy and various drug combinations are required to do 
this more effectively. However, the best way to increase patient compliance may be 
fixed combinations of two or more drugs in a single pill. With further research into 
mechanisms of action and development of new drugs, it became evident that the most 
effective combinations were those whose mechanisms are complementary or syner-
gistic. Thus, for the treatment of hypertension, the use of fixed combination therapy 
is gaining ground as a more practical and convenient approach for today’s clinical 
practice.
As we stand in the early years of the 21st century, with hundreds of antihypertensive 
drugs at our disposal, it is difficult to believe that 60 years ago there was absolutely 
nothing available for the treatment of hypertension. In fact, it was not even universally 
accepted that the “benign” or “essential” hypertension needed to be treated, unless it 
entered the malignant phase. At that point, it was treated with desperate measures, such 
as pyrogens or poisons causing circulatory shock or with radical surgical procedures, 
such as severance of sympathetic tracts or bilateral adrenalectomy.
Throughout the 1950s and 1960s several classes of antihypertensive agents be-
came available and were tested in clinical trials.1,2 The results indicated not only that 
lowering elevated blood pressure (BP) was beneficial, but also that the optimal BP 
target was much lower than the initial target of 160/95 mmHg, which was later set 
at 140/90 and more recently at 130/80, whereas normal BP is now considered to be 
120/80 or less. Indeed, several studies have now confirmed that average differences 
of 10/5 mmHg may translate into decreases of 20-40% in the rate of cardiovascular 
and cerebrovascular complications. However, it also became apparent that optimal 
targets could rarely be reached by monotherapy and indeed required multiple drugs 
in various combinations,3-14 leading patients to confusion, expense, denial. This led 
to the idea that the best way to overcome patient resistance may be fixed combina-
tions of two or more drugs in a single pill or capsule.3,4,6-12 The earliest such two- or 
three-drug combinations appeared in the 1950s and consisted mostly of a diuretic, a 
sympatholytic and a vasodilator—whatever was available at the time.
With further research into mechanisms of action and development of new drugs, 
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it became evident that the most effective combinations were 
those, whose mechanisms are complementary or synergistic.7-12 
An example of this is rendering the BP renin-dependent by 
removing salt with diuretics, so that angiotensin-inhibiting 
agents become greatly potentiated. Others have simply addi-
tive, or even less than additive effect, but may prevent each 
other’s adverse effects, such as combination of a kaliuretic with 
a potassium-sparing diuretic. Others yet, have the capacity to 
treat frequently coexisting conditions, such as high BP and 
dyslipidemia, with a single pill. Thus, the pills containing a 
fixed drug combination have evolved from random (whatever 
happens to be available), to rational (complementary or syner-
gistic) and expedient (concurrent treatment of co-morbidities). 
And the use of these combinations is gaining ground not only 
for treatment of hypertension, but also for related disorders, 
such as coronary artery disease, where initial treatment of 
acute coronary syndrome or chronic preventive treatment 
of coronary risk factors was proposed with the “tetrapill” or 
“polypill,” i.e., various fixed combinations containing a diu-
retic, an ACE inhibitor, a beta-adrenoceptor blocker, a statin 
and low-dose aspirin.15,16 Even if the more distant future may 
promise personalized therapy based on pharmacogenetics, 
the current availability of rational fixed drug combinations 
is a practical and convenient approach for today’s clinical 
practice.
R E F E R E N C E S
 1. Hamdy RC. Hypertension: a turning point in the history of 
medicine...and mankind. South Med J 2001;94:1045-1047.
 2. Freis ED. Effectiveness of drug therapy in hypertension: present 
status. Circ Res 1971;28:II-70.
 3. Bakris GL, Berkwits M. Trials that matter: the effect of a fixed-
dose combination of an angiotensin-converting enzyme inhibi-
tor and a diuretic on the complications of type 2 diabetes. Ann 
Intern Med 2008;148:400-401.
 4. Dickson M, Plauschinat CA. Compliance with antihypertensive 
therapy in the elderly: a comparison of fixed-dose combination 
amlodipine/benazepril versus component-based free-combina-
tion therapy. Am J Cardiovasc Drugs 2008;8:45-50.
 5. Bakris GL. Combined therapy with a calcium channel blocker 
and an angiotensin II type 1 receptor blocker. J Clin Hypertens 
(Greenwich) 2008;10(1 Suppl 1):27-32.
 6. Smith DH. Fixed-dose combination antihypertensives and re-
duction in target organ damage: are they all the same? Am J 
Cardiovasc Drugs 2007;7:413-422.
 7. Weir MR, Neutel JM, Bhaumik A, et al. The efficacy and safety 
of initial use of irbesartan/hydrochlorothiazide fixed-dose com-
bination in hypertensive patients with and without high car-
diovascular risk. J Clin Hypertens (Greenwich) 2007;9(12 Suppl 
5):23-30.
 8. Sharma SK, Ruggenenti P, Remuzzi G. Managing hypertension 
in diabetic patients--focus on trandolapril/verapamil combina-
tion. Vasc Health Risk Manag 2007;3:453-465.
 9. Patel A; ADVANCE Collaborative Group, MacMahon S, 
Chalmers J, Neal B, et al. Effects of a fixed combination of 
perindopril and indapamide on macrovascular and micro-
vascular outcomes in patients with type 2 diabetes mellitus 
(the ADVANCE trial): a randomised controlled trial. Lancet 
2007;370:829-840.
 10. Struijker-Boudier HA, Ambrosioni E, Holzgreve H, et al. The 
need for combination antihypertensive therapy to reach target 
blood pressures: what has been learned from clinical practice 
and morbidity-mortality trials? Int J Clin Pract 2007;61:1592-
1602.
 11. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-
dose combinations improve medication compliance: a meta-
analysis. Am J Med 2007;120:713-719.
 12. Basile JN. Fixed-dose combination therapy in the treatment of 
hypertension: ready for prime time. South Med J 2007;100:343-
344.
 13. Gavras I, Gavras H. The debate goes on--what is your choice? 
Am J Cardiol 2005;95:53-54.
14. Ribeiro AB, Gavras H. Angiotensin II antagonists: clinical expe-
rience in the treatment of hypertension, prevention of cardio-
vascular outcomes and renal protection in diabetic nephropathy 
and proteinuria. Arq Bras Endocrinol Metabol 2006;50:327-333.
 15. Fahey T, Brindle P, Ebrahim S. The polypill and cardiovascular 
disease. BMJ 2005; 330:1035
 16. Reddy KS. The preventive polypill — much promise, insuffi-
cient evidence. N Engl J Med 2007; 356:212.
